FX.co ★ Labcorp Launches H5 Bird Flu Molecular Test In U.S.

Labcorp Holdings Inc. (LH) has announced the introduction of a new molecular test for the H5 strain of bird flu in the United States, excluding New York State. This innovative test is designed to detect potential human cases of the virus. Utilizing advanced polymerase chain reaction (PCR) technology, the test employs a validated specific reagent to identify the genetic material of the H5 virus accurately. This launch is in response to a growing number of human bird flu cases, particularly among dairy and poultry workers in the U.S. As of now, Labcorp's shares are trading at $229.51, a slight decrease of 0.05 percent on the New York Stock Exchange.